India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 mln

IND Swift Laboratories

06/09/2023 09:53

BENGALURU, Sept 6 (Reuters) - India's Ind-Swift
Laboratories  ISLB.NS  said on Wednesday it would sell its
active pharmaceuticals ingredients (API) and contract research
and manufacturing services (CRAMS) business to Synthimed Labs in
a deal with an enterprise value of 16.50 billion rupees ($198.50
million).
 
 ($1 = 83.1238 Indian rupees)

 (Reporting by Ashish Chandra in Bengaluru; Editing by Savio
D'Souza)
 ((ashish.chandra@thomsonreuters.com; +91 7982114624;))